Bridget Martell, M.A., M.D.

Senior Scientific Advisor

Dr. Martell began working with Kura in November 2017 and has served as Senior Scientific Advisor since August 2020. She is a high impact, results-oriented scientific biotech executive with broad and profound experience in clinical development and medical affairs across a range of therapeutic areas from first in human to approval and commercialization. Dr. Martell brings deep scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®️️, Elelyso®️️, Intermezzo®️️, the trastuzumab biosimilars Ogiviri®️️, as well as secondary indications for Pradaxa®️️ and Sutent®️️. In addition to her work at Kura, she is an Entrepreneur in Residence at the Yale Office of Cooperative Research. Previously, Dr. Martell held executive roles at companies including Juniper Pharmaceuticals, where she served as Chief Medical Officer and SVP of New Product Development, and at Pfizer, where her roles included Biosimilars Medical Head and Clinical Team Leader for Sutent®️️ GU solid tumors in the Oncology Business Unit. She began her clinical investigation career at Yale with a Career Development Award and in the Robert Wood Johnson Clinical Scholar Program. Dr. Martell holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University, and an M.D. from The Chicago Medical School. She is board certified in both Internal and Addiction Medicine.